A_phase_IA_trial_of_sequential_administration_recombinant_DNA-produced_interferons:_combination_recombinant_interferon_gamma_and_recombinant_interferon_alfa_in_patients_with_metastatic_renal_cell_carcinoma._This_study_investigated_the_effects_of_sequentially_administered_recombinant_interferon_gamma_(rIFN_gamma)_and_recombinant_interferon_alfa_(rIFN_alpha)_in_36_patients_with_metastatic_renal_cell_carcinoma_(RCC)._rIFN_alpha_was_subcutaneously_administered_daily_for_70_days_at_dosages_that_varied_(2.5,_5,_10,_and_20_x_10(6)_U/m2)_across_four_cohorts_of_patients._Within_each_cohort_of_patients_receiving_a_given_dose_of_rIFN_alpha,_three_subsets_of_patients_received_either_30,_300,_or_1,000_micrograms/m2_rIFN_gamma._rIFN_gamma_was_administered_intravenously_for_5_days_every_third_week,_6_hours_prior_to_administration_of_rIFN_alpha._Dose-limiting_toxicity_(DLT)_included_constitutional_symptoms,_leukopenia,_nephrotic_syndrome_with_acute_renal_failure,_hypotension_associated_with_death,_and_congestive_heart_failure._DLT_was_related_more_often_to_the_rIFN_alpha_dose_level_than_to_rIFN_gamma_dose_level._Maximum-tolerated_dose_(MTD)_was_10_x_10(6)_U/m2_rIFN_alpha_and_1,000_micrograms/m2_rIFN_gamma._Six_patients_failed_to_complete_a_minimum_of_21_days_of_therapy_due_to_toxicity_or_rapid_progression_of_disease._Clinical_responses_were_seen_in_eight_of_30_assessable_patients._Two_patients_experienced_complete_remission_and_have_remained_in_complete_remission_20+_and_22+_months._An_additional_six_patients_have_shown_partial_responses_for_4_to_18+_months._One_patient_in_partial_remission_continues_to_show_slow_regression_of_pulmonary_and_liver_lesions_off_therapy_with_rIFNs._Clinical_responses_have_remained_durable_for_patients_with_complete_remissions_and_patients_with_partial_remissions._The_results_of_this_study_suggest_that_toxicities_associated_with_combination_rIFN_therapy_can_be_reduced_by_administering_these_agents_sequentially_as_opposed_to_simultaneously.